Microsoft decided to invest an additional 700 million dollars in Poland, Polish Prime Minister Donald Tusk said on Monday.

Nvidia (NVDA 2.63%) stock is currently down 12% from its all-time high. It suffered a sharp sell-off in January after China-based start-up DeepSeek asserted that it had trained a competitive artificial intelligence (AI) model using a fraction of the computing power that had been deployed by leading U.S.-based developers like OpenAI.

BEIJING, Feb. 17, 2025 (GLOBE NEWSWIRE) -- Niu Technologies (“NIU” or “the Company”) (NASDAQ: NIU), the world's leading provider of smart urban mobility solutions, today announced that it will report its financial results for the fourth quarter and full year 2024 before the U.S. market opens on Monday, March 17, 2025.

GSK PLC has bagged approval for its Penmenvy meningitis vaccine by the US Food and Drug Administration. Designed to target five major serogroups of meningitis-causing Neisseria meningitidis bacteria, GSK on Monday said the jab had been green lit for 10 to 25 year olds.

CyberArk excels in privileged access management, offering superior solutions compared to competitors like Okta. Financially, CyberArk boasts better gross margins, a leaner balance sheet, and higher free cash flow per unit of capital employed than Okta. Despite a small total addressable market, CyberArk's disciplined acquisitions and strategic positioning in PAM make it a compelling investment.

AMD has declined 45% from its highs in early 2024. Nvidia leads in AI chip performance and ecosystem, but AMD offers better value for money. Considering the market growth rates of AMD's underlying business segments, the company could be undervalued by up to 34%.

Flexibility in investment philosophy is crucial; recent cautiousness with growth stocks has led to downgrading Ingersoll Rand from 'buy' to 'hold'. Ingersoll Rand's Q4 2024 financial performance missed expectations, with revenue and earnings per share falling short, and slower growth forecasted for 2025. The Industrial Technologies and Services segment showed minimal growth, while Precision and Science Technologies grew due to acquisitions, not organic growth.

NEW YORK, NY / ACCESS Newswire / February 17, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=129954&wire=1 or contact Joseph E. Levi, Esq.

Ferrari ended 2024 with strong results, beating expectations and providing a promising outlook for 2025. The company's business model thrives on brand desirability and scarcity, with consistent execution and favourable demand/supply ratios. For 2025, Ferrari is expected to achieve higher growth driven by new models and non-car segments, including key catalysts like the EV launch and Lewis Hamilton's first year.

British healthcare real estate investment trust Assura has rejected a 1.56 billion pound ($1.96 billion) proposal from KKR and pension fund Universities Superannuation Scheme, the U.S.-based private equity group said on Monday.

NEW YORK, NY / ACCESS Newswire / February 17, 2025 / If you suffered a loss on your Crocs, Inc. (NASDAQ:CROX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/crocs-inc-lawsuit-submission-form?prid=129953&wire=1 or contact Joseph E. Levi, Esq.

Gold holds above $2,900 as Fed rate cut bets grow, while Silver stabilizes near $32. Can safe-haven demand push prices higher amid global uncertainty?

TAIPEI , Feb. 17, 2025 /PRNewswire/ -- CTCI Group announced today that two group companies, CTCI Corporation and ECOVE Environment Corporation, have been selected for inclusion in S&P Global's Sustainability Yearbook 2025. CTCI Corp. was named as the top 1% corporate sustainability performer in the construction and engineering category, with the best Corporate Sustainability Assessment (CSA) score, for three years in a row.

PARIS, Feb. 17, 2025 (GLOBE NEWSWIRE) -- FTI Consulting, Inc (NYSE: FCN) today announced the appointment of Timothée Fraisse as a Senior Managing Director in the firm's Corporate Finance & Restructuring segment in France.

Press Release Nokia upgrades Orange Jordan's broadband network gateway to enhance connectivity across the Kingdom #MWC25 State-of-the-art Nokia 7750 SR BNG deployed to elevate broadband services and user experience in Jordan. Strategic upgrade to 76 sites across the Kingdom reduces operational costs and boosts network efficiency.

This is my latest article where I provide predictions of upcoming dividend increases from companies with long-term dividend growth histories. After a busy early February, the pace of dividend increases slowed down as we moved into the latter half of the month, with only 10 companies boosting their annual dividend. But included in that number are several significant companies, including the widely followed Coca-Cola, Walmart and Home Depot.

Danaher Corp. has faced market punishment recently, but maintains strong margins and impressive FCF despite a tough year, indicating resilience and potential for future growth. The company's strategic capital allocation, including share buybacks and acquisitions, suggests management is positioning for long-term value creation, despite short-term pessimism. Danaher's bioprocessing segment shows consistent growth, and the upcoming patent cliff is expected to provide significant tailwinds, boosting demand for their life science equipment.

U.S. rig counts rise for a third week, raising concerns about oversupply. Will this cap oil and natural gas prices, or is there still room for a rally?

Provident Financial Services is a U.S. regional bank focused on mortgage lending in New Jersey, Pennsylvania, and New York. The bank's Q4 2024 results reflected the final costs of the merger with Lakeland Bancorp. Looking ahead to 2025, the bank expects no additional merger costs and a stable net interest margin.

I rate Pfizer a sell for the next 18–24 months. I expect continued headwinds from Medicare Part D redesign and patent expirations for Eliquis and Prevnar-13 in 2026. Medicare changes will cut $1 billion from 2025 revenue, with PFE now responsible for 20% of catastrophic drug costs. Danuglipron could be Pfizer's turnaround catalyst if late stage trials succeed in 2025. I expect its potential launch in late 2026 or early 2027 to boost investor sentiment.